December 3, 2025
This video discusses how data from what happens after first-line (1L) treatment progression can help doctors refine and personalize first-line treatment strategies for patients with EGFR-mutated non-small cell lung cancer (NSCLC). It builds on findings from recent clinical trials and real-world outcomes to show how patterns of resistance, progression timing, and molecular changes after 1L treatment (such as emerging resistance mutations or MET status) can inform whether to use monotherapy, combination therapy, or other approaches up front. The goal is to use post-progression insights to choose the most effective initial therapy and planning for later lines of treatment—ultimately improving sequencing decisions and overall patient outcomes.
